POSITIONING AND MARKET POTENTIAL OF CMS-024 (YSL, TYROSERLEUTIDE) IN HEPATIC CACNER IN CHINA
The report is a comprehensive analysis of the competitive landscape of Hepatic cancer drugs under development in China with an objective to figure out the market potential and positioning of China Medical System’s lead drug candidate – CMS-024 (Tyroserleutide, PhIII). China is the most important market for Hepatic cancer drugs as more than half of worldwide incidence of hepatic cancer occur in China.
CMS-024 is targeted in the early stage setting as an adjuvant treatment, where surgery and local ablation are the first line treatment options. Surgery is associated with a very high recurrence rate (35-65% within 5 years), and hence a number of drugs are being developed to address this potential unmet need. This 21 page presentation will provide a complete clinical profile of CMS-024, positioning of this tripeptide in current treatment paradigm of HCC in China, CMS-024 clinical profile vis-à-vis competition in adjuvant HCC setting and in the unresectable HCC setting and the market potential of CMS-024.
CMS-024 is targeted in the early stage setting as an adjuvant treatment, where surgery and local ablation are the first line treatment options. Surgery is associated with a very high recurrence rate (35-65% within 5 years), and hence a number of drugs are being developed to address this potential unmet need. This 21 page presentation will provide a complete clinical profile of CMS-024, positioning of this tripeptide in current treatment paradigm of HCC in China, CMS-024 clinical profile vis-à-vis competition in adjuvant HCC setting and in the unresectable HCC setting and the market potential of CMS-024.
1. EXECUTIVE SUMMARY
2. DRUG OVERVIEW- CMS-024/YSL/TYROSERLEUTIDE
3. CMS-024 – MECHANISTIC EVIDENCE OF ROLE IN HEPATIC CANCER
4. REGULATORY AND CLINICAL DEVELOPMENT OF CMS-024- CHRONOLOGY OF EVENTS
5. CMS-024 –KEY FINDINGS FROM PRECLINICAL DATA
6. CMS-024- RESULTS OF REPORTED PHI/II CLINICAL STUDY AND KEY CONCLUSION FROM THE RESULTS
7. PH III CLINICAL TRIAL DESIGN OF CMS-024 IN DETAIL - DO RECENT CHANGES IN TRIAL DESIGN POST DISCUSSION WITH SFDA ARE POSITIVE OR NEGATIVE?
Post surgical adjuvant setting- A better target than unresectable HCC or not?
8. PIPELINE DRUGS IN DEVELOPMENT IN ADJUVANT SETTING POST SURGERY IN HCC
Iodine I 131 ethiodized oil
Low dose thalidomide
Thymopentin
Nexavar
Cytokine induced killer cell
PI-88
9. CMS-024, HOW IT STANDS AGAINST NEXAVAR IN UNRESECTABLE HCC?
Clinical data comparison of Tyroserleutide vs. Nexavar in Asian patient pool
Clinical data comparision of late stage pipeline drugs in treatment of HCC
a) Sutent (PFE)
b) Brivanib ( BMY)
c) ABT-869 (ABT)
10. HEPATIC CANER- POTENTIAL MARKET IN CHINA
11. CONCLUSION:
CMS- 024 fits where in Current treatment Paradigm for treatment of HCC?
Surgery vs. local ablation therapy for treatment of early stage HCC? - How it will impact to potential of CMS-024?
Sales estimates and launch timeline of CMS-024 in China market
Approval and pricing
ANNEXURE
About CMS
Patent of CMS-024
Preclinical studies and important scientific publications
2. DRUG OVERVIEW- CMS-024/YSL/TYROSERLEUTIDE
3. CMS-024 – MECHANISTIC EVIDENCE OF ROLE IN HEPATIC CANCER
4. REGULATORY AND CLINICAL DEVELOPMENT OF CMS-024- CHRONOLOGY OF EVENTS
5. CMS-024 –KEY FINDINGS FROM PRECLINICAL DATA
6. CMS-024- RESULTS OF REPORTED PHI/II CLINICAL STUDY AND KEY CONCLUSION FROM THE RESULTS
7. PH III CLINICAL TRIAL DESIGN OF CMS-024 IN DETAIL - DO RECENT CHANGES IN TRIAL DESIGN POST DISCUSSION WITH SFDA ARE POSITIVE OR NEGATIVE?
Post surgical adjuvant setting- A better target than unresectable HCC or not?
8. PIPELINE DRUGS IN DEVELOPMENT IN ADJUVANT SETTING POST SURGERY IN HCC
Iodine I 131 ethiodized oil
Low dose thalidomide
Thymopentin
Nexavar
Cytokine induced killer cell
PI-88
9. CMS-024, HOW IT STANDS AGAINST NEXAVAR IN UNRESECTABLE HCC?
Clinical data comparison of Tyroserleutide vs. Nexavar in Asian patient pool
Clinical data comparision of late stage pipeline drugs in treatment of HCC
a) Sutent (PFE)
b) Brivanib ( BMY)
c) ABT-869 (ABT)
10. HEPATIC CANER- POTENTIAL MARKET IN CHINA
11. CONCLUSION:
CMS- 024 fits where in Current treatment Paradigm for treatment of HCC?
Surgery vs. local ablation therapy for treatment of early stage HCC? - How it will impact to potential of CMS-024?
Sales estimates and launch timeline of CMS-024 in China market
Approval and pricing
ANNEXURE
About CMS
Patent of CMS-024
Preclinical studies and important scientific publications
